



The regulation and politics of food from genetically engineered animals



Alison Van Eenennaam, Ph.D.
Cooperative Extension Specialist
Animal Biotechnology and Genomics
Department of Animal Science
University of California, Davis
alvaneennaam@ucdavis.edu
Ph: (530) 752-7942



<http://animalscience.ucdavis.edu/animalbiotech/>



56% of Americans oppose scientific research into the genetic modification of animals

<http://pewagbiotech.org/research/2005update/2005summary.pdf>





Unnatural genetic modification of animals.....





Unnatural genetic modification of animals..... like these ones!





The appearance of most genetically engineered animals is rather unremarkable.....





Outline

- The “livestock revolution”
- Extant genetically-engineered (GE) animals for agriculture
- US Regulatory approach
- Case study: AquAdvantage salmon
- Politics





Proportional increase in world head of livestock 1961-2004; data from FAO (2005)




Figure based on Pretty, J. (2008) Agricultural sustainability: concepts, principles and evidence. *Philosophical Transactions of the Royal Society B-Biological Sciences* 363:447-465.

Extant GE livestock applications

<u>ENVIRONMENTAL</u>	<u>Species</u>	<u>Gene</u>	<u>Approach</u>
Decreased P in manure	Swine	Phytase	Transgene overexpression
<u>DISEASE RESISTANCE</u>			
Mastitis resistance	Cattle, Goat	Lysostaphin; Lysozyme	Transgene expression
BSE resistance	Goat, Cattle	Prion	RNAi transgene; knockout
Visna virus resistance	Sheep	Visna virus envelope gene	Transgene expression
Mastitis resistance	Goats	Lysozyme	Transgene expression
Avian influenza	Chicken	Influenza decoy	Transgene expression
Bacterial resistance	Channel Catfish	Cecropin B gene	Transgene expression
<u>PRODUCT QUALITY</u>			
Increased ω -3 fatty acids in meat	Swine	n-3 fatty acid desaturase	Clone/Transgene expression
Increase cheese yield from milk	Cattle	β -casein, κ -casein	Clone/Transgene expression
<u>PRODUCTIVITY</u>			
Enhanced growth rate	Many fish species	Growth Hormone	Transgene expression
Enhanced milk production	Swine	α -lactalbumin	Transgene expression
Enhanced growth rate	Swine	Growth hormone	Transgene expression
Enhanced growth rate	Swine	Insulin-like-growth factor	Transgene expression

Fahrenkrug et al. 2010. Precision Genetics for Complex Objectives in Animal Agriculture.

J. Anim Sci. 88: 2530-2539



Fast growing salmon

The founder female was generated in 1989 – 21 years ago

Nature Biotechnology 10:176 – 181. **1992**



© 1992 Nature Publishing Group <http://www.nature.com/naturebiotechnology>

GROWTH ENHANCEMENT IN TRANSGENIC ATLANTIC SALMON BY THE USE OF AN “ALL FISH” CHIMERIC GROWTH HORMONE GENE CONSTRUCT

Shao Jun Du, Zhiyuan Gong, Garth L. Fletcher¹, Margaret A. Shears¹, Madonna J. King¹, David R. Idler¹ and Choy L. Hew*

Research Institute, The Hospital for Sick Children and Departments of Clinical Biochemistry and Biochemistry, University of Toronto, Toronto, Canada M5G 1L5. ¹Ocean Sciences Centre, Memorial University of Newfoundland, St. John's, Newfoundland, Canada A1C 5S7. *Corresponding author.

We have developed an “all fish” growth hormone (GH) chimeric gene construct by using an antifreeze protein gene (AFP) promoter from ocean pout linked to a chinook salmon GH cDNA clone. After microinjection into fertilized, nonactivated Atlantic salmon eggs via the micropyle, transgenic Atlantic salmon were generated. The presence of the transgene was



Enviropig™ (Low-phosphorus manure)



© 2001 Nature Publishing Group <http://biotech.nature.com>

RESEARCH ARTICLE

Nature Biotechnology 19, 741–745 . **2001**

Pigs expressing salivary phytase produce low-phosphorus manure

Serguei P. Golovan^{1,2}, Roy G. Meidinger², Ayodele Ajakaiye³, Michael Cottrill¹, Miles Z. Wiederkehr⁴, David J. Barney⁴, Claire Plante⁵, John W. Pollard⁵, Ming Z. Fan³, M. Anthony Hayes⁶, Jesper Laursen^{7,8}, J. Peter Hjorth⁷, Roger R. Hacker³, John P. Phillips^{2,*}, and Cecil W. Forsberg^{1,*}

To address the problem of manure-based environmental pollution in the pork industry, we have developed the phytase transgenic pig. The saliva of these pigs contains the enzyme phytase, which allows the pigs to digest the phosphorus in phytate, the most abundant source of phosphorus in the pig diet. Without this enzyme, phytate phosphorus passes undigested into manure to become the single most important manure pollutant of pork production. We show here that salivary phytase provides essentially complete digestion of dietary phytate phosphorus, relieves the requirement for inorganic phosphate supplements, and reduces fecal phosphorus output by up to 75%. These pigs offer a unique biological approach to the management of phosphorus nutrition and environmental pollution in the pork industry.



“reduces fecal phosphorus output by up to 75%”

www.uoguelph.ca/enviropig



Mastitis-resistant cows (inflammation of mammary gland)



ARTICLES

nature
biotechnology

Nature Biotechnology 23:445-451. **2005**

Genetically enhanced cows resist intramammary *Staphylococcus aureus* infection

Robert J Wall¹, Anne M Powell¹, Max J Paape², David E Kerr³, Douglas D Bannerman², Vernon G Pursel¹, Kevin D Wells⁴, Neil Talbot¹ & Harold W Hawk¹

Mastitis, the most consequential disease in dairy cattle, costs the US dairy industry billions of dollars annually. To test the feasibility of protecting animals through genetic engineering, transgenic cows secreting lysostaphin at concentrations ranging from 0.9 to 14 mg/ml in their milk were produced. *In vitro* assays demonstrated the milk's ability to kill *Staphylococcus aureus*. Intramammary infusions of *S. aureus* were administered to three transgenic and ten nontransgenic cows. Increases in milk somatic cells, elevated body temperatures and induced acute phase proteins, each indicative of infection, were observed in all of the nontransgenic cows but in none of the transgenic animals. Protection against *S. aureus* mastitis appears to be achievable with as little as 3 mg/ml of lysostaphin in milk. Our results indicate that genetic engineering can provide a viable tool for enhancing resistance to disease and improve the well-being of livestock.

<http://www.nature.com/naturebiotechnology>

www.ars.usda.gov





GE Chickens That Don't Transmit Bird Flu

Breakthrough could prevent future bird flu epidemics

Suppression of Avian Influenza Transmission in Genetically Modified Chickens

Jon Lyall,³ Richard M. Irvine,² Adrian Sherman,³ Trevelyan J. McKinley,³ Alejandro Núñez,² Auriol Purdie,^{3*} Linzy Outtrim,² Ian H. Brown,² Genevieve Rolleston-Smith,³ Helen Sang,³† Laurence Tiley³†‡

Infection of chickens with avian influenza virus poses a global threat to both poultry production and human health that is not adequately controlled by vaccination or by biosecurity measures. A novel alternative strategy is to develop chickens that are genetically resistant to infection. We generated transgenic chickens expressing a short-hairpin RNA designed to function as a decoy that inhibits and blocks influenza virus polymerase and hence interferes with virus propagation. Susceptibility to primary challenge with highly pathogenic avian influenza virus and onward transmission dynamics were determined. Although the transgenic birds succumbed to the initial experimental challenge, onward transmission to both transgenic and nontransgenic birds was prevented.

The diversity of avian influenza viruses (AIVs) and their propensity for inter-species transmission make them a global threat to animal and public health communities. Cross-species transmission of influenza viruses may occur directly or be facilitated by inter-



mediate host species that amplify and diversify virus populations, notably domestic chickens, ducks, and pigs (1). Although control of AIV infection in its wild aquatic bird reservoir is impractical, control of AIV in domesticated hosts is possible (2). The diversity of viral antigenic sub-



Science 331:223-226. **2011** SCIENCE VOL 331 14 JANUARY 2011 223

<http://www.roslin.ed.ac.uk/public-interest/gm-chickens>





In a letter to the FDA dated April 26, **1993**, AquaBounty Technologies (then A/F Protein) initiated discussions with the FDA seeking regulatory guidance for development and approval of a GE Atlantic salmon intended to grow faster than conventionally bred Atlantic salmon.

- In January 2009, the Food and Drug Administration issued a final guidance for industry on the regulation of genetically engineered (GE) animals (had 28,000 comments on draft!!)
- FDA plans to regulate GE animals under the new animal drug provisions of the Federal Food, Drug, and Cosmetic Act (FFDCA), and the National Environmental Policy Act (NEPA).

187

Guidance for Industry

Regulation of Genetically Engineered Animals
Containing Heritable Recombinant DNA Constructs

Final Guidance

<http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM113903.pdf>



"New Animal Drug" approach

- The recombinant DNA (rDNA) construct is a new animal drug because it is **"an article intended to alter the structure or function"** of the animal.
- New animal drugs may be approved if they are shown to be safe and effective for the intended use.
- In a hierarchical risk-based multistep scientific review the agency examines the safety of the rDNA construct to the animal, the safety of food from the animal, and any environmental impacts posed, as well as the extent to which the performance claims made for the animal are met.





"New Animal Drug" approach



- Because of the requirements set forth in the National Environmental Protection Act (NEPA) and FDA environmental impact regulations, the agency typically must prepare an environmental assessment (EA) for each New Animal Drug Application (NADA)
- FDA has to consider the possible effects on the human environment and possible risk mitigation strategies that may arise from the specific conditions of use that are the subject of the NADA.
- There will be a 60 day comment period following the release of the FDA's Environmental Assessment
- In the event that the EA results in a finding that a significant environmental impact may result, an Environmental Impact Statement (EIS) may need to be prepared.



FDA NEWS RELEASE

FOR IMMEDIATE RELEASE

January 15, 2009

Media Inquiries:
Michael Herndon, (301) 796-4673
Consumer Inquiries:
888-INFO-FDA

FDA Issues Final Guidance on Regulating Genetically Engineered Animals

En Español

The U.S. Food and Drug Administration today issued a final guidance for industry on the regulation of genetically engineered (GE) animals under the new animal drug provisions of the Federal Food, Drug and Cosmetic Act (FFDCA). The guidance, titled "The Regulation of Genetically Engineered Animals Containing Heritable rDNA Constructs," clarifies the FDA's statutory and regulatory authority, and provides recommendations to producers of GE animals to help them meet their obligations and responsibilities under the law.

Genetic engineering generally refers to the use of recombinant DNA (rDNA) techniques to introduce new characteristics or traits into an organism. When scientists splice together pieces of DNA and introduce a spliced DNA segment into an organism to give the organism new properties, it is called rDNA technology. The spliced piece of DNA is called the rDNA construct. A GE animal is one that contains an rDNA construct intended to give the animal new characteristics or traits.

"Genetic engineering is a cutting edge technology that holds substantial promise for improving the health and well being of people as well as animals. In this document, the agency has articulated a scientifically robust interpretation of statutory requirements," said Randall Lutter, Ph.D., deputy commissioner for policy. "This guidance will help the FDA efficiently review applications for products from GE animals to ensure their safety and efficacy."

The FDA released the draft guidance in September 2008 with a 60-day public comment period, and received about 28,000 comments. The agency has summarized and responded to these comments on the Web site listed below.

The FDA's Center for Veterinary Medicine (CVM) has been working with developers of GE animals on both early stage and more mature applications.

"At this time, it is our intent to hold public scientific advisory committee meetings prior to making decisions on GE animal-related applications" said Bernadette Dunham, D.V.M., Ph.D., director of CVM.

The FFDCA defines "articles (other than food) intended to affect the structure or any function of the body of man or other animals" as drugs. An rDNA construct that is in a GE animal and is intended to affect the animal's structure or function meets the definition of an animal drug, whether the animal is intended for food, or used to produce another substance. Developers of these animals must demonstrate that the construct and any new products expressed from the inserted construct are safe for the health of the GE animal and, if they are food animals, for food consumption.

The guidance also describes the manufacturer's responsibility in meeting the requirements for environmental review under the National Environmental Policy Act.

For more information:


- [Genetically Engineered Animals](#)

"Increase transparency, clarity, and public confidence in the GE animal regulatory process"






Date	Event
September 1995	AquaBounty submits Investigational New Animal Drug application with FDA for fast-growing salmon with intent to commercialize



Fish reach adult size in 16 to 18 months instead of 30 months





Same-age siblings – one carrying a hemizygous copy of the transgene





Retrieved from "AquAdvantage" image search on web Frankenfish





Product Definition for the AquAdvantage Salmon

Product Identity

Triploid hemizygous, all-female Atlantic salmon (*Salmo salar*) bearing a single copy of the α -form of the opAFP-GHc2 rDNA construct at the α -locus in the EO-1a lineage.

Claim

Significantly more of these Atlantic salmon grow to at least 100 g within 2700 deg C days than their comparators.

Limitations for Use

These Atlantic salmon are produced as eyed-eggs for grow-out only in the FDA-approved physically-contained fresh water culture facility.





Food/Feed Safety: Does food or feed from the GE animal pose any risk to humans or animals consuming edible products from GE animals compared with the appropriate non-transgenic comparators?

Conclusion of food/feed safety evaluations:

*"We therefore conclude the food from AquAdvantage Salmon (the **triploid** ABT salmon) that is the subject of this application is as safe as food from conventional Atlantic salmon, and that there is a reasonably certainty of no harm from the consumption of food from this animal. No animal feed consumption concerns were identified".*

Page 62, AquAdvantage Briefing packet. <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/VeterinaryMedicineAdvisoryCommittee/UCM224762.pdf>



Environmental Safety: What is the likelihood that AquAdvantage Salmon will escape the conditions of confinement?

Where will the AquAdvantage Salmon be raised?

If approved, the AquAdvantage Salmon will be raised **in inland tanks**. They will not be raised in ocean net pens. Any change would require a new application and approval.

There are multiple and redundant physical and mechanical barriers in place in the water systems at the PEI egg production and Panama grow-out facilities to prevent the accidental release of eggs and/or fish to nearby aquatic environments. These barriers have been designed specifically to prevent the escape of different life stages of AquAdvantage Salmon. Both facilities have a minimum of three to five mechanical barriers in place for all internal flow streams which release water to the environment. Standards and has been verified by an FDA inspection or site visit. Therefore, the likelihood is considered very low that AquAdvantage Salmon will escape from confinement at these sites.







Summary of advantages of land-based (inland tank) **SUSTAINABLE** aquaculture



- Shorter production time – 16-18 months versus 30 months
- Shorter time to harvest diminishes the risk of disease and resultant use of chemotherapeutics/antibiotics
- Culture in a land based, contained (e.g recirculating) system reduces spread of disease in the environment (and wild salmon populations)
- Lower Food Conversion Ratio (i.e. LESS lbs feed eaten per lb product produced) - feed is major cost of animal production!
- Does not spawn during growout (more energy available for growth AKA less energy wasted on reproduction!).
- Land based salmon culture systems can be located adjacent to major markets, reducing freight costs and the associated environmental impact i.e. locally-grown "locivovre" source of fish



Date	Event
September 1995	AquaBounty submits Investigational New Animal Drug (INAD) application with FDA for fast-growing salmon with intent to commercialize
September 2010	Public Veterinary Medicine Advisory Committee meeting to consider data on safety and efficacy of AquaAdvantage salmon Held in Washington DC





Did the public meeting achieve its stated goal of increasing transparency, clarity, and public confidence in the GE animal regulatory process?



Wenonah Hauter of Food and Water Watch carries a box with public comments opposing FDA approval of genetically engineered salmon.



Frankenfood, Coming Soon to a Store Near You?

Published September 20, 2010 | FoxNews.com

Print Email Share Comments (0) Recommend 799 Text Size



Reuters/Barrett & McKay Photo/AquaBounty Technologies

A genetically engineered AquAdvantage Salmon (background) is compared to an Atlantic salmon of the same age (foreground). The U.S. Food and Drug Administration will hold a two-day meeting starting September 19 to discuss whether to approve the altered fish for U.S. consumers to eat.

WASHINGTON – Watch for a new section between "frozen foods" and "organic" in your supermarket: genetically engineered. That is, if the government approves the so-called "frankenfoods" for sale.

The [Food and Drug Administration](#) Monday began a two-day look at the issue Monday, focusing on genetically modified salmon, which would be the first such food approved for human consumption.

The agency has already said the salmon, which grow twice as fast as conventional ones, are safe to eat. But salmon act as a genetic gatekeeper in this case: Approve them and open the door for a variety of other genetically engineered animals, including an environmentally friendly pig that is being developed in Canada or cattle that are resistant to mad cow disease.

"For future applications out there the sky's the limit," said [David Edwards](#) of the [Biotechnology Industry Association](#). "If you can imagine it, scientists can try to do it."

CAES 10/12/2011

Industry Fights Altered Salmon

Article

NEW

Stock Quotes

Comments (5)

Email Print Save This Like 52 Text

By ALICIA MUNDY And BILL TOMSON

The fishing industry and politicians from commercial-fishing states are mobilizing against a possible Food and Drug Administration approval of genetically modified salmon for the American dinner table.

"Putting unlabeled, genetically altered salmon in the marketplace is simply irresponsible, and the FDA needs to strongly consider what impacts this will have before they approve this Frankenfish," Sen. Lisa Murkowski, a Republican from Alaska, said Thursday.



View Full Image

Associated Press

Icy Bay crewmen remove sockeye salmon from their net in July. Commercial fisheries are fighting the introduction of genetically altered salmon.

The resistance could raise difficulties for the FDA, whose scientists have said the AquAdvantage Atlantic salmon developed by AquaBounty Technologies Inc. is safe for human consumption. AquAdvantage contains a growth-hormone gene from another salmon that helps it grow twice as fast as conventional farmed fish.

A coalition that includes Pacific Coast trollers, Atlantic fishing companies and organic-yogurt maker Stonyfield Farm says the genetically altered salmon might threaten their livelihoods by spreading unease about salmon and other foods.

"This stuff is not healthy for people, and it's not like our fresh fish," said Angela Sanfilippo, president of the Gloucester Fishermen's Wives Association of Massachusetts.

Ms. Sanfilippo's group and others have joined with 39 lawmakers who wrote to the FDA this week asking the agency to stop its approval process for the genetically modified salmon.

They cited concerns about "human health and environmental risks" from the AquAdvantage salmon.

Animal Biotechnology and Genomics Education



In September 2010, more than 40 members of Congress sent letters requesting FDA halt the approval of the AquaBounty salmon.



"The FDA's hastily completed approval process puts American consumers and the environment at risk. GE salmon could be devastating to fishing and coastal communities, our food source, and already depleted wild salmon populations. The FDA should put the interests and safety of American families and our ocean resources above special interests"

Rep. DeFazio (D-OR) September 2010.



Fish facts



- In 2006 the world consumed 110.6 million metric tons of fish with ~ half coming from aquaculture
- Need to increase another 28.8 MMT by 2030
- Fish represent less than 8 percent of total U.S. consumption of meat, poultry and fish in 2001, salmon represented just 1 percent.
- Since 2001, salmon has ranked third among fish species consumed in the United States, after shrimp and canned tuna and accounted for about 14 percent of U.S. fish consumption.



Salmon facts

- 1996: World farmed salmon production exceeds wild salmon harvest.
- During the years 2000-2004, Americans consumed an average of about 0.28 MMT of salmon annually, of which:
 - one-third was Pacific salmon and two-thirds was Atlantic salmon
 - one-third was wild and two-thirds was farmed
 - one-third was domestic production and two thirds was imported
- 99% of the Atlantic salmon consumed in the US was farmed – almost all from aquaculture operations in Canada, Chile, Norway and Scotland
- Atlantic salmon do not interbreed with Pacific salmon i.e. can not harm Pacific salmon populations





Average Annual U.S. Salmon Consumption, 2000-2004

(1000 metric tons, import and processing weight basis)



	Pacific	Atlantic	Total
Total	105	180	284
Canned	47	0	47
Frozen	36	24	60
Fresh	22	156	178
Domestic	81	10	91
Imported	24	170	193
Wild	97	2	99
Farmed	7	178	185

	Pacific	Atlantic	Total
Total	100%	100%	100%
Canned	45%	0%	16%
Frozen	34%	13%	21%
Fresh	21%	87%	63%
Domestic	77%	6%	32%
Imported	23%	94%	68%
Wild	93%	1%	35%
Farmed	7%	99%	65%

October 2011
Davis, CA

SALMON ATLANTIC
FILLET COLOR
ADDED FRESH

Club
Price

6⁹⁹

per lb

This Tue. Oct. 11

Non-Member Price 11⁹⁹_{lb}

Product 221

Fresh Atlantic
Salmon Fillets
Farm Raised

\$8⁹⁹

Wild Card

SALMON ATLANTIC
FILLET FRESH

Club
Price

6⁹⁹

lb

Wild Caught
Fresh
KING SALMON
FILLETS

Origin: U.S.A.

\$17.99



Natural
Sweet



Date	Event
September 1995	AquaBounty submits Investigational New Animal Drug application with FDA for fast-growing salmon with intent to commercialize
September 2010	Public Veterinary Medicine Advisory Committee meeting to consider data on safety and efficacy of AquAdvantage salmon
June 15 th 2011	House of Representatives passed a voice vote amendment that prohibit use of FDA funds to approve any application for approval of genetically engineered salmon. Offered by Reps. Don Young (R-AK) and Lynn Woolsey (D-CA).

Young argued that the modified fish are unnatural and their production could create competition for his state's fishing industry. In a statement, Young said he had deep concern about the salmon, which he dubbed "Frankenfish."

"Frankenfish is uncertain and unnecessary," Young said. "Should it receive approval as an animal drug, it clears the path to introduce it into the food supply. My amendment cuts them off before they can get that far. Any approval of genetically modified salmon could seriously threaten wild salmon populations as they grow twice as fast and require much more food."



The Science and Regulation of Food from Genetically Engineered Animals

Authors:

Alison L. Van Eenennaam (Chair)
University of California
Davis

Eric M. Hallerman
Virginia Polytechnic Institute
and State University
Blacksburg

William M. Muir
Purdue University
West Lafayette, Indiana

6/20/2011 Washington Roll-out of the CAST report to House Committee on Agriculture, including the lead staffer for Cong. Don Young (R-AK, sponsor of the 6/15/11 amendment cutting FDA funds for oversight of GE salmon)





Date	Event
September 1995	AquaBounty submits Investigational New Animal Drug application with FDA for fast-growing salmon with intent to commercialize
September 2010	Public Veterinary Medicine Advisory Committee meeting to consider data on safety and efficacy of AquAdvantage salmon
June 2011	House of Representatives passed a voice vote amendment that prohibit use of FDA funds to approve any application for approval of genetically engineered salmon. Offered by Reps. Don Young (R-AK) and Lynn Woolsey (D-CA).
July 2011	Eight senators urge FDA Commissioner Margaret A. Hamburg, MD, to stop her agency from further considering approving the GE salmon. The letter expresses concerns about potential threats to public and environmental health and economic harm for wild salmon producers. The letter also indicates that the Senate could concur with a measure passed by the House of Representatives

The letter was signed by Sens. Daniel Akaka (HI), Mark Begich (AK), Maria Cantwell (WA), Jeff Merkley (OR), Barbara Mikulski (MY), Lisa Murkowski (AK), Patty Murray (WA), and Jon Tester (MT).



“There is little benefit to society if attempts to increase public participation in the regulatory process are used as an opportunity to vilify technology.”

Transgenic salmon: a final leap to the grocery shelf?

Alison L Van Eenennaam & William M Muir Nature Biotechnology (2011) **29**: 706–710.

Despite being caught up in regulatory proceedings for 15 years or more, AquAdvantage salmon, the first animal genetically engineered (GE) for food purposes, continues to raise concerns. Are any of these concerns scientifically justified?

© 2011 Nature America, Inc. All rights reserved.

The tortuous passage of AquAdvantage salmon through the US regulatory system provides a stark reminder of the adage that sometimes it is good not to be first. A fast-growing transgenic fish containing a gene encoding Chinook salmon growth hormone under the control of an antifreeze protein promoter and terminator from ocean pout, AquAdvantage salmon has been subjected to one of the most prolonged, if not exhaustive, regulatory assessments in history. This process culminated last September with a meeting of the Veterinary Medicine Advisory Committee (VMAC) as well as a public hearing, together with the release of a comprehensive health and safety briefing and an environmental assessment package on the transgenic animal developed by AquaBounty Technologies of Waltham, Massachusetts. Despite VMAC’s determination



AquaBounty Technologies



Animal Agriculture Coalition (see below) sent leaders in the House and Senate a letter defending the use of a science-based review process to evaluate genetically engineered products (August 2011).



- American Association of Bovine Practitioners
- American Association of Swine Veterinarians
- American Association of Veterinary Laboratory Diagnosticians
- American Farm Bureau Federation
- American Feed Industry Association
- American Horse Council
- American Meat Institute
- American Rabbit Breeders Association
- American Sheep Industry Association
- American Society of Animal Science
- American Veal Association
- American Veterinary Medical Association
- Animal Agriculture Alliance
- Animal Health Institute

- Association of American Veterinary Medical Colleges
- Association of Veterinary Biologics Companies
- Biotechnology Industry Organization
- Catfish Farmers of America
- Council for Agricultural Science and Technology
- Federation of Animal Science Societies
- Holstein Association USA, Inc.
- Livestock Exporters Association of the USA
- Livestock Marketing Association
- National Aquaculture Association
- National Association of Federal Veterinarians
- National Cattlemen's Beef Association
- National Chicken Council
- National Dairy Herd Improvement Association
- National Farmers Union



Date	Event
September 1995	AquaBounty submits Investigational New Animal Drug application with FDA for fast-growing salmon with intent to commercialize
September 2010	Public Veterinary Medicine Advisory Committee meeting to consider data on safety and efficacy of AquaAdvantage salmon
June 2011	House of Representatives passed a voice vote amendment that prohibit use of FDA funds to approve any application for approval of genetically engineered salmon. Offered by Reps. Don Young (R-AK) and Lynn Woolsey (D-CA).
July 2011	Eight senators urge FDA Commissioner Margaret A. Hamburg, MD, to stop her agency from further considering approving the GE salmon. The letter expresses concerns about potential threats to public and environmental health and economic harm for wild salmon producers. The letter also indicates that the Senate could concur with the measure passed by the House of Representatives (above)
August 2011	Three Massachusetts representatives write to Commissioner Hamburg to urge her to let the FDA continue its scientific investigation. The representatives' letter states that the FDA has spent 15 years working with AquaBounty to collect health, safety, and environmental data; sought consultation and expertise from other federal agencies; and evaluated the safety and effectiveness of the genetic modification.



Published September 12, 2011, 05:40 AM

Tweet 1

Share 3

+1 0

Print

E-mail

Senators offer amendments to ag appropriations bill

WASHINGTON — Amendments to keep the Food and Drug Administration from approving “Frankenfish” genetically modified salmon and to stop the Agriculture Department from cutting back on the use of potatoes and other starchy vegetables in the school lunch program are among those that might be offered on the Senate floor if the Senate version of the fiscal year 2012 Agriculture appropriations bill comes up there as an independent piece of legislation.

By: Jerry Hagstrom, Special to Agweek

September 12, 2011

Sen. Dianne Feinstein, D-Calif., told Murkowski, “I don’t like genetically modified anything,” but added that this situation had “caught us cold” and that she would prefer to “do due diligence” before voting on the amendment.

<http://www.agweek.com/event/article/id/19068>

September 13, 2011

Alison- Senator Feinstein has asked me to prepare a substantive briefing for her of the potential impacts of the AquaBounty Salmon on California. Generally, she has questions regarding the process used to approve the fish (treating it as an animal drug) and is concerned about the environmental impacts as well.

Would you be available to speak on this subject?

Devin Rhinerson

Office Of Senator Dianne Feinstein





Dr. Calestous Juma, Harvard's Kennedy School of Government, at a 6/23/11 hearing to examine the benefits of agricultural biotechnology held by the House Agriculture Committee's Subcommittee on Rural Development, Research, Biotechnology, and Foreign Agriculture



"I understand this House passed an amendment to the Agriculture Appropriations Bill that would effectively prevent the Food and Drug Administration from completing its safety assessment of the first food fish that makes use of (bio)technology. . . It is not this particular fish that is at stake. It is the principle behind the amendment and its wider ramifications. It sends the message to the rest of the world that the science-based regulatory oversight as embodied in the FDA review process is subject to political intervention.

Furthermore, it signals to the world that the United States may **cede its leadership position in the agricultural use of biotechnology**. I believe it is imperative that the US stay the course it has set in not letting politics interfere with its science-based regulatory system that is truly the envy of the world."

Chinese work on transgenic animals



Production of recombinant human lysozyme in the milk of pig to improve the diarrhea-resistance ability of piglets

In the swine industry pathogenic infections have a significant negative impact on neonatal survival. The team lead by Prof. Ning Li in China Agricultural University has worked on improving the ability of piglets to resist diarrhea disease since 2008 and successfully produced many transgenic pigs with expressing recombinant human lysozyme in the milk. To date, the total number of transgenic pigs with recombinant human lysozyme is up to 272. The experiment has entered the productive experiment stage.

Production of transgenic human lysozyme in the milk of transgenic pigs

Production of transgenic human lysozyme in the milk of transgenic pigs

B vector: **hLZ1** **hLZ2** **hLZ3** **CK**

2967bp

C **hLZ1** **CK** **hLZ2** **hLZ3**

347ED₉

Transgenic pigs specifically express phytase in the parotid gland

CAU & SCAU

Total got 21 transgenic founders of reduced phosphorus content in the feces

Phosphorus in transgenic pig feces **21.4%**

Pig cages used for testing phosphorus metabolism

Phytase transgenic cloned pigs



shRNA Transgenic Pig Display Significant Resistance to the Infection of FMDV

the shRNA expressive vector pMD19-EN3D2B against both nonstructural protein 2B and polymerase 3D of FMDV was transferred, and 23 transgenic cloned pigs generated [2010] by Prof. Li Ning in China Agriculture University.

in the 10 ID₅₀ and 100 ID₅₀ challenge, transgenic cloned pigs all performed the ability of anti-FMDV, and one transgenic cloned pig was protected during all the challenge period.

FMDV and FMDV genes

pMD19-EN3D2B

Transgenic cloned pig VS **Non-transgenic cloned pig**

The 'Mad Pig Disease'

sfat-1 Transgenic Cattle increased the Omega-3 fatty acids in dairy and beef

Prof. Guangpeng Li group from Inner Mongolia University generated sfat-1 transgenic dairy cattle and beef cattle in 2009 and 2010. These cattle was supposed to increase the omega-3 fatty acids of beef or milk.

November 2010, Da Lian

June 2009

sfat-1 transgenic cattle was generated, sfat-1 was expressed in multi-tissues and improved the fatty acids composition in milks.

a, sfat-1 transgenic cattle; b, Expression of sfat-1 gene was detected with RT-PCR in tissues of bovines. Lane 1 to 3 and 6 to 10: liver muscle kidney lung heart of wild type and transgenic cattle; c, fatty acids profile of transgenic and wild type cattle in milk.

Fatty acid	Wild type	sfat-1 Transgenic
18:2n-6	0.08	0.08
20:4n-6	0.03	0.03
18:3n-3	0.05	0.05
20:5n-3	0.01	0.01
22:5n-3	0.01	0.01
22:6n-3	0.01	0.01
24:6n-3	0.01	0.01
24:7n-3	0.01	0.01
24:8n-3	0.01	0.01
24:9n-3	0.01	0.01
24:10n-3	0.01	0.01
24:11n-3	0.01	0.01
24:12n-3	0.01	0.01
24:13n-3	0.01	0.01
24:14n-3	0.01	0.01
24:15n-3	0.01	0.01
24:16n-3	0.01	0.01
24:17n-3	0.01	0.01
24:18n-3	0.01	0.01
24:19n-3	0.01	0.01
24:20n-3	0.01	0.01
24:21n-3	0.01	0.01
24:22n-3	0.01	0.01
24:23n-3	0.01	0.01
24:24n-3	0.01	0.01
24:25n-3	0.01	0.01
24:26n-3	0.01	0.01
24:27n-3	0.01	0.01
24:28n-3	0.01	0.01
24:29n-3	0.01	0.01
24:30n-3	0.01	0.01
24:31n-3	0.01	0.01
24:32n-3	0.01	0.01
24:33n-3	0.01	0.01
24:34n-3	0.01	0.01
24:35n-3	0.01	0.01
24:36n-3	0.01	0.01
24:37n-3	0.01	0.01
24:38n-3	0.01	0.01
24:39n-3	0.01	0.01
24:40n-3	0.01	0.01
24:41n-3	0.01	0.01
24:42n-3	0.01	0.01
24:43n-3	0.01	0.01
24:44n-3	0.01	0.01
24:45n-3	0.01	0.01
24:46n-3	0.01	0.01
24:47n-3	0.01	0.01
24:48n-3	0.01	0.01
24:49n-3	0.01	0.01
24:50n-3	0.01	0.01